Trials / Active Not Recruiting
Active Not RecruitingNCT04106349
Observational Real-life Study of Cabozantinib in Monotherapy or in Combination With Nivolumab in Advanced Renal Cell Carcinoma (RCC)
REPLICA: Real Patient Life Treatment With Cabozantinib in Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic RCC: a Descriptive and Prospective Non Interventional Study.
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 150 (estimated)
- Sponsor
- Ipsen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to describe the real-life use of Cabometyx® in monotherapy or in combination with nivolumab in Belgium in patients with advanced or metastatic Renal Cell Carcinoma (1st, 2nd and later lines of treatment)
Conditions
Timeline
- Start date
- 2020-03-03
- Primary completion
- 2027-03-31
- Completion
- 2027-03-31
- First posted
- 2019-09-27
- Last updated
- 2026-03-31
Locations
20 sites across 1 country: Belgium
Source: ClinicalTrials.gov record NCT04106349. Inclusion in this directory is not an endorsement.